876589-09-2 Usage
Uses
Used in Pharmaceutical Industry:
Tert-butyl 3-(chloromethyl)piperidine-1-carboxylate is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity allow for the development of new drugs with improved therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, tert-butyl 3-(chloromethyl)piperidine-1-carboxylate is employed as a crucial intermediate for the production of agrochemicals. Its versatile reactivity enables the creation of novel compounds with enhanced pesticidal or herbicidal effects.
Used in Organic Synthesis:
Tert-butyl 3-(chloromethyl)piperidine-1-carboxylate is used as a building block in organic synthesis for the preparation of a wide range of compounds. Its structural diversity and potential for modification make it an essential component in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-butyl 3-(chloromethyl)piperidine-1-carboxylate is applied as a valuable intermediate for the development of new therapeutic agents. Its unique properties facilitate the design and synthesis of innovative drugs with improved efficacy and selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 876589-09-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,6,5,8 and 9 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 876589-09:
(8*8)+(7*7)+(6*6)+(5*5)+(4*8)+(3*9)+(2*0)+(1*9)=242
242 % 10 = 2
So 876589-09-2 is a valid CAS Registry Number.
876589-09-2Relevant academic research and scientific papers
Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents
Miller, John F.,Turner, Elizabeth M.,Gudmundsson, Kristjan S.,Jenkinson, Stephen,Spaltenstein, Andrew,Thomson, Michael,Wheelan, Pat
experimental part, p. 2125 - 2128 (2010/06/13)
The lead optimization of a series of N-substituted benzimidazole CXCR4 antagonists is described. Side chain modifications and stereochemical optimization led to substantial improvements in potency and protein shift to afford compounds with low nanomolar a
CHEMICAL COMPOUNDS
-
Page/Page column 63, (2010/10/20)
The present invention provides novel compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind specifically to the chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 and/or CCR5 of a target cell.
